Is Lithium a Psychotropic Drug?

Lithium is a psychotropic drug, classified specifically as a mood stabilizer (sometimes called a normothymic) and used primarily to treat bipolar disorder and treatment-resistant depression.¹ But calling lithium “psychotropic” only scratches the surface. It is one of the oldest and most unusual medications in psychiatry, with effects that range from suicide prevention to neuroprotection, and a safety profile that demands careful monitoring unlike almost any other drug in daily clinical use.

What “Psychotropic” Actually Means Here

A psychotropic drug is any substance that crosses into the brain and alters mood, perception, thinking, or behavior. That umbrella covers antidepressants, antipsychotics, anti-anxiety medications, stimulants, and mood stabilizers. Lithium falls squarely into the mood-stabilizer category, where it sits alongside medications like valproic acid and certain anticonvulsants. But lithium is unique in that category because it is a simple element, number three on the periodic table, rather than a complex synthetic molecule. In clinical use, it is given as a salt, most commonly lithium carbonate or lithium citrate, which dissolves and releases lithium ions into the bloodstream.

The United States was actually the 50th country to approve lithium, finally allowing it on the market in 1970, decades after Australian psychiatrist John Cade first demonstrated its calming effects in manic patients.² That slow acceptance had less to do with efficacy doubts and more to do with the fact that lithium is a natural element that could not be patented, giving pharmaceutical companies little financial incentive to push it through regulatory hurdles. Its unusual history partly explains why lithium occupies a strange position in modern psychiatry: widely regarded by specialists as the single most effective mood stabilizer, yet often underused compared with newer, more heavily marketed alternatives.

How Lithium Alters Brain Chemistry

For a drug that has been in clinical use for over seven decades, lithium’s known molecular targets are surprisingly few. The main ones include a signaling enzyme called GSK-3, a group of related enzymes that includes inositol monophosphatases, and phosphoglucomutase.³ By inhibiting GSK-3, lithium influences a wide range of cellular processes downstream, from how neurons grow and survive to how certain genes get switched on or off. The inositol pathway, meanwhile, affects signaling cascades that neurons rely on to communicate, which may be part of why lithium dampens both the highs and lows of mood episodes.

At the level of individual brain cells, lithium modulates several neurotransmitter systems. In hypothalamic neurons, lithium boosts the activity of GABA, the brain’s primary inhibitory signaling chemical, through mechanisms that operate independently of normal nerve firing.⁴ Meanwhile, lithium’s effects on glutamate, the brain’s main excitatory chemical, are more complicated. In the frontal cortex, the dose and duration of lithium exposure determine whether glutamate levels go up or down, and these shifts seem to involve crosstalk between the two neurotransmitter systems.⁵ In healthy human volunteers given lithium for two weeks, glutamine-related compounds dropped in the basal ganglia, a brain region involved in movement and reward, suggesting that this rebalancing of excitatory signaling may be part of how the drug works even outside of disease.⁶

This mix of effects, fine-tuning both excitatory and inhibitory signaling rather than simply pushing the brain in one direction, helps explain why lithium works as a stabilizer rather than just a sedative or a stimulant. It is not numbing the brain; it is adjusting the gain on several systems at once.

The Gold Standard for Bipolar Disorder

Lithium is frequently described as the gold standard treatment for bipolar disorder, and that reputation holds up under scrutiny. A systematic review and meta-analysis of randomized trials found that lithium is effective for treating acute mania, including episodes with psychotic features, and works as a maintenance treatment to prevent future manic episodes.⁷ An analysis of current clinical studies found lithium to be superior to several commonly used alternatives, including aripiprazole, valproic acid, and quetiapine, for improving manic symptoms, and it was associated with lower relapse rates than valproic acid.⁸

Where the evidence gets thinner is on lithium’s ability to prevent depressive episodes in bipolar disorder. While its anti-manic properties are robust, the data on long-term depression prevention remain unclear.⁷ This asymmetry matters because bipolar depression is often the more disabling pole of the illness. In practice, many patients on lithium end up needing additional medications to manage their depressive episodes.

Lithium for Treatment-Resistant Depression

Beyond bipolar disorder, lithium has a well-supported role in boosting the effectiveness of antidepressants that are not working well enough on their own. This strategy, known as augmentation, has been studied in over 30 open-label studies and 10 placebo-controlled trials. A meta-analysis of those controlled trials found that patients who added lithium to their antidepressant responded at a rate of about 41%, compared with roughly 14% in the placebo group.⁹ Lithium is considered a cost-effective augmentation option with a well-established efficacy profile compared with alternatives like second-generation antipsychotics or ketamine.¹⁰

One particularly striking trial looked at patients with unipolar major depression who had initially responded to lithium augmentation and then were randomized to continue lithium or switch to placebo. Among the 15 patients on placebo, seven (47%) relapsed, including one suicide. Among the 14 who continued lithium, not a single patient relapsed.¹¹ The trial was small, but the result was dramatic enough that it contributed to lithium augmentation becoming a standard recommendation in treatment guidelines for depression that has not responded to initial antidepressant therapy.

The Anti-Suicide Effect

Lithium’s apparent ability to reduce suicidal behavior is one of its most discussed and most debated properties. Observational evidence accumulated over decades suggests that long-term lithium treatment reduces the risk of suicide and suicide attempts in people with bipolar disorder, with possibly similar benefits in recurrent major depression.¹² Some evidence suggests this effect may operate partly independently of mood stabilization itself, possibly through lithium’s influence on impulsivity, agitation, and dysphoric mood, and it may persist even at blood levels below the standard therapeutic range.¹³

However, a randomized trial in U.S. veterans with major depression or bipolar disorder found no difference between lithium and placebo for preventing repeat suicide-related outcomes.¹⁴ That trial was methodologically rigorous, and its null finding has shaken some of the confidence around this claim. The tension between the observational data (which consistently point to a benefit) and this particular randomized trial (which did not) remains unresolved. Some researchers argue that lithium’s anti-suicide effect may be real but operate over longer treatment periods or in specific subgroups, making it hard to capture in a standard trial format. This is an area where the science is genuinely unsettled.

The Narrow Safety Window

Lithium’s therapeutic range is notoriously tight. Blood levels are typically checked 12 hours after the last dose, and dosing has to be adjusted carefully to stay within a narrow concentration band.¹⁵ Too low, and the drug doesn’t work. Too high, and you risk toxicity, which can cause tremor, confusion, seizures, and in severe cases, organ damage. This is why lithium requires regular blood monitoring, something most other psychiatric medications do not demand. Anything that shifts your body’s fluid balance, from dehydration to a change in kidney function to starting a new blood-pressure medication, can push lithium levels into dangerous territory.

This monitoring burden is one of the main reasons clinicians sometimes avoid prescribing lithium in favor of newer, easier-to-manage medications. It is also why patient education matters: people on lithium need to understand the importance of staying hydrated, recognizing early signs of toxicity like persistent tremor or nausea, and keeping up with scheduled lab work.

Long-Term Thyroid and Kidney Risks

Chronic lithium use carries well-documented risks to the thyroid and kidneys. A large cohort study found that lithium roughly doubled the risk of developing hypothyroidism compared with non-lithium treatments, and that risk climbed further at higher serum lithium levels.¹⁶ Lithium was also associated with an increased risk of moderate chronic kidney disease, though the same study did not find a significant increase in more advanced kidney failure. A separate retrospective cohort confirmed similar effect sizes, also identifying elevated calcium as an additional risk.¹⁷

What do these risks look like across very long treatment periods? A case series examining five patients who had taken lithium for 40 or more years found mild-to-moderate kidney disease in all of them, with one woman developing severe thyroid dysfunction requiring thyroid hormone replacement.¹⁸ These are sobering findings, but the clinical calculus is rarely straightforward. For a person with severe bipolar disorder, the alternative to lithium may be poorly controlled mood episodes, hospitalizations, and suicide risk. Physicians typically manage the endocrine and renal risks through regular lab monitoring and early intervention rather than by avoiding the drug altogether.

Lithium During Pregnancy

Lithium exposure during early pregnancy carries an increased risk of cardiac malformations in the developing fetus. A large cohort study found cardiac defects in about 2.4% of lithium-exposed infants, compared with roughly 1.2% in unexposed infants. The risk was dose-dependent: at daily doses of 600 mg or less, the increase was not statistically significant, but at doses above 900 mg the risk roughly tripled.¹⁹ One specific defect historically linked to lithium exposure is Ebstein’s anomaly, a rare malformation of the tricuspid valve in the heart, though it remains uncommon even among lithium-exposed pregnancies.²⁰

These findings leave women with bipolar disorder facing a genuinely difficult decision. Stopping lithium during pregnancy risks destabilizing a serious psychiatric illness at a particularly vulnerable time. Continuing it, especially at higher doses, carries a measurable risk to the fetus. Current practice typically involves a detailed risk-benefit conversation, potentially lowering the dose before conception, and close fetal cardiac monitoring if the decision is to continue treatment.

What Lithium Does to Brain Structure

One of the more compelling findings in lithium research is evidence that the drug protects and may even enlarge certain brain structures. In rat hippocampal neurons, lithium increased dendritic length and number and protected neurons against excitotoxic damage. It also raised levels of BDNF, a protein critical for neuron growth and survival, while dialing down the expression of genes that promote cell death.²¹ In humans, lithium treatment has been associated with increased hippocampal volume in people with bipolar disorder, likely driven by these same neurotrophic effects.²²

Functional brain imaging tells a related story. Lithium monotherapy appears to normalize connectivity patterns between the amygdala, the brain’s emotional alarm center, and prefrontal regions involved in emotional regulation. In patients with bipolar disorder, the direction of this shift depended on the patient’s baseline mood: those who started out hypomanic showed decreased connectivity in a network that was abnormally overactive, while those who started out depressed showed the opposite adjustment.²³ A separate randomized trial comparing lithium to quetiapine in first-episode mania patients found that lithium specifically reduced abnormally elevated connectivity between the ventral striatum and the cerebellum.²⁴ In other words, lithium does not simply suppress brain activity; it steers abnormal connectivity patterns back toward normal.

Lithium also appears to protect mitochondria, the cellular structures responsible for energy production. Long-term treatment enhanced mitochondrial function in neuronal cell lines and protected against chemically-induced mitochondrial damage in animal models, effects that were shared by valproic acid but may be especially relevant for lithium’s neuroprotective profile.²⁵

Lithium Orotate Supplements

Walk into a health food store or browse supplement websites and you may encounter lithium orotate, sold in low-dose capsules as a “natural” alternative to prescription lithium carbonate. These are not the same thing, and the distinction matters a lot. Prescription lithium carbonate delivers therapeutic amounts of lithium ions at doses carefully tuned to produce a specific blood level. Over-the-counter lithium orotate supplements typically contain far smaller amounts of elemental lithium.

The theoretical appeal of lithium orotate is that it may cross the blood-brain barrier more efficiently than lithium carbonate, potentially allowing lower doses with fewer side effects.²⁶ A recent mouse study found that lithium orotate blocked amphetamine-induced hyperactivity at roughly one-tenth the dose required for lithium carbonate, and it did so without producing the kidney stress markers or thyroid hormone changes seen with lithium carbonate at its effective dose.²⁷ Those results are intriguing but come from animal models only.

Complicating the picture, an older rat study found that lithium orotate actually produced higher tissue lithium concentrations in the kidney and heart and lowered kidney function compared to lithium carbonate, leading the authors to recommend against its use in patients.²⁸ The two animal studies reach strikingly different conclusions, and no well-designed human clinical trials exist for lithium orotate in psychiatric conditions. Without human data, the over-the-counter supplements exist in a regulatory gray zone: legal to sell, but unproven for the conditions people buy them hoping to treat.

Trace Lithium in Drinking Water

One of the more surprising lines of lithium research has nothing to do with pills. Lithium occurs naturally in groundwater at trace concentrations that vary widely by geography, and multiple ecological studies have asked whether areas with higher natural lithium levels have lower suicide rates. A systematic review and meta-analysis of these studies found a consistent inverse association between lithium levels in publicly available drinking water and suicide mortality rates.²⁹

The correlation is interesting, but these are ecological studies, meaning they compare populations across regions rather than tracking individuals. One study found the association only held in municipalities with both higher lithium levels and high rates of affective disorders, suggesting the relationship may not be as straightforward as “more lithium in water equals fewer suicides.”³⁰ A biomonitoring study in Portugal that measured urinary lithium concentrations in people from regions with different suicide rates found no statistically significant differences after proper correction for multiple comparisons.³¹ So while the meta-analytic signal is real, it remains unclear whether trace lithium in water is causally protective or simply correlated with other regional factors. Proposals to add lithium to public water supplies, analogous to fluoridation for dental health, have surfaced periodically but remain firmly in the speculative territory.

Lithium and Alzheimer’s Disease Research

Lithium’s neuroprotective properties have drawn the attention of dementia researchers. Because lithium inhibits GSK-3, an enzyme involved in the production of amyloid plaques and the hyperphosphorylation of tau protein, both hallmarks of Alzheimer’s disease, there has been growing interest in whether lithium could slow cognitive decline. A 2024 study published in Nature found that in normal aging mice, endogenous low-level lithium preserved cognitive function, reduced brain inflammation, and suppressed amyloid generation. In Alzheimer’s mouse models, it protected against amyloid deposition, tau buildup, neuroinflammation, and loss of synapses and myelin.³²

These findings are still largely preclinical, and translating neuroprotection in mice to a meaningful delay or prevention of Alzheimer’s in humans is a notoriously difficult leap. But the mechanistic rationale is sound, and small clinical trials in humans are underway. If lithium, or a lithium formulation designed for lower systemic exposure, could slow early-stage cognitive decline, it would represent a remarkable second life for a drug that has already been reshaping psychiatry for over seventy years.